Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Changes in Beneficial Ownership · 4

Allurion Technologies, Inc.

Changes in Beneficial Ownership

Filed Jul 23, 2026Accepted Jul 23, 2026, 5:10 PM EDTFiling CIK 1964979Accession 0001231919-26-000786
Share

Structured filing — 4

form4-07232026_090723.xml

Open full document ↗

Filing details

Report period
2026-07-21
Issuer
ALLURION TECHNOLOGIES, INC.
Issuer CIK
0001964979
Trading symbol
ALUR
No longer subject to Section 16
Checked

Reporting owner 1

Name
RTW INVESTMENTS, LP
Reporting owner CIK
0001493215
Relationship
10% owner
Address
40 10TH AVENUE, 7TH FLOOR, NEW YORK, NY, 10014

Reporting owner 2

Name
WONG RODERICK
Reporting owner CIK
0001493280
Relationship
10% owner
Address
40 10TH AVENUE, 7TH FLOOR, NEW YORK, NY, 10014

Non-derivative transactions

Non-derivative transactions · 4 reported rows
SecurityTransaction dateCodeAmountA / DPrice (USD)Owned afterOwnershipNature of ownership
Common Stock, $0.0001 par value per share2026-07-21J · Form 4[F1]209,254D[F1]0ISee footnotes[F2][F3]
Common Stock, $0.0001 par value per share2026-07-21J · Form 4[F4]161,807D[F4]0ISee footnotes[F2][F5]
Common Stock, $0.0001 par value per share2026-07-21J · Form 4[F6]19,934D[F6]0ISee footnotes[F2][F7]
Common Stock, $0.0001 par value per share2026-07-21J · Form 4[F8]1,771D[F8]0ISee footnotes[F2][F9]
Table key
J · Form 4
Other acquisition or disposition; see explanation
D
Disposed
I
Indirect

Derivative transactions

Derivative transactions · 4 reported rows
SecurityConversion / exercise price (USD)Transaction dateCodeAmountA / DPrice (USD)ExercisableExpiresUnderlying securityUnderlying sharesOwned afterOwnershipNature of ownership
Pre-Funded Warrant (Right to Buy)0.00012026-07-21J · Form 4[F1]209,254A[F1][F10][F10]Common Stock209,254209,254ISee Footnotes[F2][F3]
Pre-Funded Warrant (Right to Buy)0.00012026-07-21J · Form 4[F4]161,807A[F4][F10][F10]Common Stock161,807161,807ISee footnotes[F2][F5]
Pre-Funded Warrant (Right to Buy)0.00012026-07-21J · Form 4[F6]19,934A[F6][F10][F10]Common Stock19,93419,934ISee footnotes[F2][F7]
Pre-Funded Warrant (Right to Buy)0.00012026-07-21J · Form 4[F8]1,771A[F8][F10][F10]Common Stock1,7711,771ISee footnotes[F2][F9]
Table key
J · Form 4
Other acquisition or disposition; see explanation
A
Acquired
I
Indirect

Footnotes

F1
On July 21, 2026, RTW Master Fund, Ltd. ("Master Fund") entered into an Exchange Agreement with the Issuer pursuant to which the Master Fund exchanged, for no additional consideration, 209,254 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 209,254 shares of the Issuer's Common Stock at an exercise price of $0.0001 per share (a "Pre-Funded Warrant").↩ 1↩ 2↩ 3↩ 4
F2
RTW Investments, LP (the "Adviser") manages certain funds that directly hold the securities reported herein, including the Master Fund, RTW Innovation Master Fund, Ltd. ("RTW Innovation"), RTW Biotech Opportunities Operating Ltd. ("RTW Biotech Fund") and other funds or accounts managed by the Adviser (each, an "Other RTW Fund"). Roderick Wong, M.D. serves as the Managing Partner and Chief Investment Officer of the Adviser. Each Reporting Person disclaims beneficial ownership of the securities reported on this Form 4 except to the extent of its or his pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8
F3
Held directly by Master Fund.↩ 1↩ 2
F4
On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which the RTW Innovation exchanged, for no additional consideration, 161,807 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 161,807 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
F5
Held directly by RTW Innovation.↩ 1↩ 2
F6
On July 21, 2026, RTW Biotech Fund entered into an Exchange Agreement with the Issuer pursuant to which the RTW Biotech Fund exchanged, for no additional consideration, 19,934 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 19,934 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
F7
Held directly by RTW Biotech Fund.↩ 1↩ 2
F8
On July 21, 2026, RTW Innovation entered into an Exchange Agreement with the Issuer pursuant to which Other RTW Fund exchanged, for no additional consideration, 1,771 shares of the Issuer's Common Stock for a Pre-Funded Warrant exercisable for 1,771 shares of the Issuer's Common Stock.↩ 1↩ 2↩ 3↩ 4
F9
Held by an Other RTW Fund.↩ 1↩ 2
F10
The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the holder shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the holder, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8

Remarks

On June 18, 2026, the Issuer effected a 1-for-15 reverse stock split. The share counts herein reflect the reverse stock split.

Signature 1

Signed
/s/ Roderick Wong, M.D. - For RTW Investments, L.P., By: Roderick Wong, M.D., Managing Partner
Date
2026-07-23

Signature 2

Signed
/s/ Roderick Wong, M.D.
Date
2026-07-23

Filed exhibits

Company context

Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.

Current securities

Historical securities (4)

Recent company filings

  1. 25-NSE - filed by NEW YORK STOCK EXCHANGE LLC regarding ALLURION TECHNOLOGIES, INC.Oct 13, 2026
  2. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 24, 2026
  3. NT 10-Q filingAug 14, 2026
  4. Entry into a Material Definitive Agreement · Termination of a Material Definitive Agreement · Unregistered Sales of Equity SecuritiesJul 24, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsJul 23, 2026

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.